Journal article

Evaluation of six commercial SARS-CoV-2 serology assays detecting different antibodies for clinical testing and serosurveillance

Suellen Nicholson, Theo Karapanagiotidis, Arseniy Khvorov, Celia Douros, Francesca Mordant, Katherine Bond, Julian Druce, Deborah A Williamson, Damian Purcell, Sharon R Lewin, Sheena Sullivan, Kanta Subbarao, Mike Catton

Open Forum Infectious Diseases | Oxford University Press (OUP)


Abstract Background Serological testing for SARS-CoV-2 complements nucleic acid tests for patient diagnosis and enables monitoring of population susceptibility to inform the COVID-19 pandemic response. It is important to understand the reliability of assays with different antigen or antibody targets to detect humoral immunity after SARS-CoV-2 infection and to understand how antibody (Ab) binding assays compare to those detecting neutralizing antibody (nAb), particularly as we move into the era of vaccines. Methods We evaluated the performance of six commercially available E..

View full abstract